<p><i><strong>Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic levels</strong></i></p>

Latham BioPharm Group, part of SIA Partners, today announced receiving a new Indefinite Delivery, Indefinite Quantity (IDIQ) contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), titled Preclinical Services for Biopharmaceuticals Product Development.

The agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models

The Tribun Health executive team is growing with the creation of a VP Pharma position to develop the expanding pharmaceutical business.

Charles River will license Hera's SRG rat (OncoRat), the first highly immunocompromised rat model

Crossing Blood-Brain Barrier and In Vivo Delivery of Negatively Charged Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

3Brain AG has announced a new technology based on a unique combination of microchips and AI that promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials - and to maximize their chances of success.

IVIM Technology, Inc. has released the most compact all-in-one intravital two-photon microscope, "IVM-MS2". IVIM Technology, Inc. is the world's first start-up that commercializes all-in-one integrated intravital microscopy equipment. Our equipment uses innovative intravital microscopy (IVM) technology originally developed by KAIST.

This three-part webinar series reviews the key considerations for design and conduct of a development plan for a monoclonal antibody (mAb) product.

Autoimmune diseases such as ulcerative colitis require chronic treatment that often causes systemic immunosuppression, increasing long-term cancer and infection risk. Reducing systemic side effects with localized treatment would greatly benefit patients.

Bringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.

Investment Adds New Capabilities and State-of-the-Art Responsible Care Environment

MR Solutions, of Guildford, UK, will be exhibiting its preclinical imaging systems at the International Society for Magnetic Resonance in Medicine (ISMRM), in Toronto, from 30 May to 5 June, 2015.

Preclinical, cryogen-free benchtop MRI scanners are now available for Class 3 and 4 laboratories

10 Science Park Road, The Alpha #01-05, Singapore Science Park II, Singapore 117684, Singapore